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Most androgenic drugs are available as esters for a prolonged depot action. However, the
enzymes involved in the hydrolysis of the esters have not been identified. There is one
study indicating that PDE7B may be involved in the activation of testosterone enanthate.
The aims are to identify the cellular compartments where the hydrolysis of testosterone
enanthate and nandrolone decanoate occurs, and to investigate the involvement of
PDE7B in the activation. We also determined if testosterone and nandrolone affect
the expression of the PDE7B gene. The hydrolysis studies were performed in isolated
human liver cytosolic and microsomal preparations with and without specific PDE7B
inhibitor. The gene expression was studied in human hepatoma cells (HepG2) exposed to
testosterone and nandrolone. We show that PDE7B serves as a catalyst of the hydrolysis
of testosterone enanthate and nandrolone decanoate in liver cytosol. The gene expression
of PDE7B was significantly induced 3- and 5- fold after 2 h exposure to 1µM testosterone
enanthate and nandrolone decanoate, respectively. These results show that PDE7B is
involved in the activation of esterified nandrolone and testosterone and that the gene
expression of PDE7B is induced by supra-physiological concentrations of androgenic
drugs.
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INTRODUCTION
Testosterone has been therapeutically used for several decades,
primarily for androgen replacement therapy in hypogonadal
men. Moreover these agents are commonly abused by athletes
and sportsmen to improve muscle mass. The abuse of these
compounds for cosmetic purposes among non-competing recre-
ational body-builders and non-athletes is a major social concern
and has become a growing health problem (Pope and Katz, 1994;
Eklof et al., 2003; Sjoqvist et al., 2008; Kanayama et al., 2009).
Synthetic analogs such as nandrolone may also have other ther-
apeutic indications such as osteoporosis and aplastic anemia
(Frisoli et al., 2005).
Most of the androgenic drugs are available as esters, e.g.,
testosterone enanthate, nandrolone decanoate, since the andro-
gen itself undergoes first pass metabolism. These drugs have
a prolonged depot action due to slow release of the lipophilic
steroid ester from the injection site. It is not known which
enzymes catalyze the hydrolysis of the esters in order to acti-
vate these pro-drugs. We have previously demonstrated that
phosphodiesterase 7B (PDE7B) is involved in the hydroly-
sis and activation of testosterone enanthate (Ekstrom et al.,
2011).
PDE7B enzyme belongs to a super-family of 11 mem-
bers (PDE1-11), all involved in the hydrolyses of intracellular
cyclic adenosine monophosphate (cAMP) and cyclic guanosine
monophosphate (cGMP) in a variety of cells (Gardner et al.,
2000; Hetman et al., 2000; Sasaki et al., 2000). The mechanisms
that regulate the expression of PDE genes are not well known.
There are two studies showing that glucucorticoids inhibit the
PDE mRNA expression (Hermsdorf et al., 1999; Ahlstrom et al.,
2005). However, whether anabolic androgenic steroids affect the
expression of PDE has not been investigated.
Here we have analyzed if PDE7B is involved in the hydrolysis
of nandrolone decanoate using human liver homogenates, micro-
somes and cytosols. Moreover we have evaluated if PDE7B gene
expression is modified by therapeutic and supra-physiological
doses of testosterone enanthate and nandrolone decanoate in
human liver cells (HepG2) using real-time PCR.
MATERIALS AND METHODS
IN-VITRO STUDIES IN HUMAN LIVER SAMPLES
Five human liver homogenates were obtained from our liver
bank (approved by the Ethics Review board in Stockholm). The
liver samples were homogenized in 50mM potassium phosphate
from Merck (Darmstadt, Germany) buffer (pH 7.4) and stored
at −80◦C until use. The incubation was performed at 37◦C
using different concentrations of nandrolone decanoate from
NMI (Lindfield, Australia), 20µL liver homogenates and Tris-
HCl from Sigma-Aldrich Chemie GmbH (Munich, Germany)
50mM pH 7.4 for a final volume of 250µL. After a selected incu-
bation time, the reaction mixture was stopped by adding 100µL
acetonitril from Merck and centrifuged 10min at 3500 rpm
prior to injection of 20µL onto a high performance liquid
chromatography system coupled to ultra-violet detection (HPLC-
UV). Esterase activity was determined by monitoring the nan-
drolone formation by analysis on an Agilent 1100 LC system
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from Agilent Technologies (Palo Alto, CA, USA) system coupled
to a UV detector Agilent 1200 sets at a wavelength of 242 nm.
The chromatographic separation was performed on a C18 Luna
(100 × 4.6, 3µm) column from Phenomenex Inc. (Torrance, CA,
USA) with an isocratic flow of acetonitril/H2O (40:60, v:v) at
1.0mL/min.
In order to determine the cellular compartment where the
hydrolysis takes place, cytosols and microsomes were prepared
and incubation assays were carried out using the same proce-
dure as for homogenates. Liver pieces were homogenized in buffer
(10mM Na/K phosphate, pH 7.4, containing 1.14% KCl) and
then centrifuged (10,000 × g at 4◦ C for 20min). The resulting
supernatant was further exposed to defined speed centrifuga-
tion, whereby a microsomal pellet and a cytosolic fraction were
obtained. The pellet was homogenized and mixed with buffer
(50mM potassium phosphate buffer, pH 7.4) and the cytoso-
lic fraction was mixed with dithiothreitol, EDTA, sucrose and
glycerol, before storage at −80◦C. The protein concentration in
liver homogenates, microsomes, and cytosols were performed
according to Lowry et al. (1951).
In order to evaluate if PDE7B is involved in the hydrolysis
of nandrolone decanoate, inhibition studies were carried out by
adding BRL50481 dissolved in DMSO, both from Sigma-Aldrich
Chemie GmbH, to the incubation assay (2.5µL of a 50mM stock
solution for a final concentration of 0.5mM). The hydrolysis of
nandrolone decanoate was also studied in the presence of caffeine
from Sigma-Aldrich Chemie GmbH dissolved in the incubation
buffer (2.5µL of a 50mM stock solution for a final concentration
of 0.5mM).
CELL CULTURE
All culture media and their ingredients were obtained from
Gibco (Life Technologies Ltd, Paisley, UK). Human liver cancer
HepG2 cells were cultured in MEM (supplemented with 5% FCS,
1% penicillin/streptomycin, 1% L-glutamine) and maintained in
humidified atmosphere at 37◦C and 5% CO2. Prior to androgen
treatment, the HepG2 cells were split and plated in 12-well plates
and pre-incubated for 2–3 days. Testosterone enanthate from
Sigma-Aldrich Chemie GmbH and nandrolone decanoate were
diluted in ethanol 99.5% from Kemetyl (Haninge, Sweden) (stock
solution of 1mM) and added to the cells for 2–48 h at various
concentrations (0.01–10µM). Other compounds were diluted in
ethanol for incubation with cells at a final concentration of 1µM
during 2 h; free testosterone and free nandrolone from NMI,
estradiol and estradiol cypionate from Sigma-Aldrich Chemie
GmbH and R1881 was kindly provided by Professor Anders
Bjartell, Karolinska Institute. The non-treated controls were incu-
bated with vehicle only. The experiments were performed in at
least four independent experiments. For RNA experiments the
cells were harvested with Trizol from Invitrogen (Paisley, UK) and
kept at −80◦C.
RNA EXTRACTION AND cDNA
Total RNA extraction from HepG2 cells was performed using
0.5mL Trizol per well according to manufacturer’s instructions.
RNA (0.5µg) was reverse transcribed into cDNA with hexamer
primer using first-strand cDNA synthesis kit from Invitrogen
according to the manufacturer’s protocol and diluted 20 times in
water.
REAL TIME PCR
The mRNA level of PDE7B in testosterone treated HepG2s was
determined by real-time PCR. Beta-actin by Applied Biosystems
(Carlsbad, CA, USA) was chosen as an endogenous housekeeping
control gene. Quantitative real-time PCR was performed using
the 7500 Fast rtPCR from Applied Biosystems. Reaction mix-
tures contained SYBR green reaction mix from Kapa Biosystems
(Woburn, MA, USA), PDE7B primers (as described in Pekkinen
et al., 2008), 4µl cDNA template in a total volume of 15µl.
Thermal cycling conditions included activation at 95◦C (10min)
followed by 40 cycles each of denaturation at 95◦C (15 s) and
annealing/elongation at 60◦C (1min). Each reaction was per-
formed in triplicate and no-template controls were included in
each experiment. The untreated sample was employed as a cal-
ibrator and the delta CT-formula was used as described in the
literature (Livak and Schmittgen, 2001). The gene expression
was quantified as the yield of the target gene relative to that of
Beta-actin gene.
DATA ANALYSIS
The hydrolysis activity, the inhibitory effect in liver sub-cellular
fractions as well as the comparison of PDE7B mRNA expression
levels between androgen-exposed and non-exposed cells were all
compared nonparametric Mann Whitney test. The results are
presented as mean ± SD if not stated otherwise. The statistical
analyses were performed using GraphPrism Software version 4.03
from GraphPad (San Diego, CA, USA) and values of P < 0.05
were considered statistically significant.
RESULTS
ACTIVITY STUDIES
To assess the cellular compartment where the nandrolone
decanoate hydrolysis takes place, we measured the esterase activ-
ity in human liver homogenates, microsomes, and cytosols. The
hydrolysis of nandrolone decanoate was similar in homogenates
(0.55 ± 0.12µmol/min/mg protein) and microsome (0.58 ±
0.06µmol/min/mg protein), whereas the activity was signifi-
cantly lower in cytosols (p < 0.045) (0.14 ± 0.02µmol/min/mg
protein) (Figure 1A).
INHIBITOR STUDIES
In a previous study we showed that the hydrolysis of testosterone
enanthate in human liver homogenates was inhibited by spe-
cific PDE7 inhibitor BRL50481. In order to evaluate if PDE7B
is also involved in the hydrolysis of nandrolone decanoate, the
specific PDE7B/PDE7A inhibitor BRL50481 was added to the
incubation assay. When BRL50481 was added to the incubation
assays, the activities were significantly inhibited by 62% in the
homogenates (p = 0.034) and 65% in the cytosols (p = 0.006).
In the microsomes, there was no inhibition in esterase activity
(Figure 1B).
To further assess if other PDEs may be involved in the hydrol-
ysis of nandrolone decanoate the non-specific PDE7B inhibitor
caffeine was tested. The general PDE inhibitor caffeine inhib-
ited the cytosolic hydrolysis (p = 0.042) (Figure 1B). There was
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FIGURE 1 | (A) Activity of sub-cellular fractions of human liver from
Caucasian donors (n = 5) on the hydrolysis of nandrolone decanoate. The
hydrolysis of nandrolone decanoate was lower in the cytosols as compared to
homogenate and microsome fractions. (B) The inhibition in hydrolyse activity
by PDE7B specific inhibitor (BRL50481) gray bars and a non-selective PDE
inhibitor (caffeine) white bars. ∗p < 0.05.
no significant difference between caffeine and BRL50481 inhibi-
tion indicating that caffeine inhibits hydrolysis to the same extent
as BRL50481. Caffeine did not inhibit the nandrolone decanoate
hydrolysis in microsomes. These results indicate that no other
PDEs are involved in the cleavage of steroid esters.
PDE7B mRNA EXPRESSION IN HepG2 CELLS
In order to study if androgen drugs affect the transcrip-
tional activity of PDE7B, testosterone enanthate and nandrolone
decanoate, were added at different concentrations (0.01–10µM)
(Figure 2A) for different times point (2–24 h) (Figure 2B) to
HepG2 cells. There was no induction at the lowest concentration
(0.01µM) used. Nandrolone decanoate significantly increased
PDE7B expression approximately 4-fold at 0.1, 1.0, and 10µM.
Testosterone enanthate significantly increased PDE7B mRNA
expression at 1µM. The gene expression was induced only after
2 h (p = 0.049 for testosterone enanthate and p = 0.026 for nan-
drolone decanoate), whereas at 5, 8, and 24 h no induction was
observed.
In order to see if testosterone and nandrolone themselves
would induce the transcription of PDE7B, free testosterone and
nandrolone were added to the cells. The free steroids (1µM)
induced the PDE7B expression after 2 h (p = 0.29) (Figure 3) to
the same extent as the esterified androgens.
In order to verify that the induction was due to an androgenic
effect, rather than an estrogenic effect, we added the synthetic
androgen receptor (AR) agonist R1881 and a significant increase
in PDE7B expression was observed (p = 0.029). Moreover, when
estradiol or estradiol cypionate was added to the cells no induc-
tion in PDE7B expression was observed (Figure 3).
DISCUSSION
In a previous in vitro study we showed that PDE7B is involved
in the hydrolysis of testosterone enanthate. Here we show that
PDE7B also activates nandrolone decanoate. Our inhibition stud-
ies indicate that the hydrolyze rate of nandrolone decanoate is
higher in microsomes than in cytosols. When the specific PDE7
FIGURE 2 | Relative PDE7B mRNA levels in HepG2 cells after exposure
to androgen esters at (A) different concentrations (µM) and incubation
time of 2h and (B) different incubation time (hours) and a concen-
tration of 1µM. The PDE7B gene expression was induced after 2 h
exposure. ∗p < 0.05.
inhibitor BRL50481 was added, the activity was significantly
decreased by 65% in the cytosols, whereas in the microsomes
no inhibition of the hydrolytic activity was observed. Our results
indicate that PDE7B is active in the cytosol compartment. This
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FIGURE 3 | PDE7B mRNA expression in HepG2 cells after 2h incubation
with 1µM of various hormones (free testosterone, nandrolone, and
estrogen, estradiol cypionate, and R1881). The androgens but not the
estrogens induced the PDE7B gene expression. ∗p < 0.05.
is in agreement with a previous study showing that the PDE7B
specific cAMP hydrolytic activity was found exclusively in the
cytosolic extracts of COS-cells (Sasaki et al., 2000). In addition to
inhibition of the PDE7B enzyme, BRL50481 also inhibits PDE7A,
an enzyme showing 70% sequence homology with PDE7B. In
contrast to PDE7B, PDE7A is active both in the cytosol and
microsomes (Han et al., 1997; Sasaki et al., 2000). Since we
did not find any inhibition in the microsomes, our results fur-
ther supports that PDE7B and not PDE7A is involved in the
hydrolysis of nandrolone decanoate. Our results indicate that
approximately 65% of a quarter of the androgen ester hydrolysis
is due to PDE7B. The remaining hydrolysis in the cytosol, as well
as the high activity found in the microsomes may be catalyzed
by other esterases and/or by non-enzymatic activity. Even though
only a minor part of the androgen hydrolysis may be catalyzed
by PDE7B in vitro, PDE7B activity may be of clinical interest
since a genetic variation in PDE7B has been shown to be asso-
ciatied with bioavailibilty of testosterone in vivo (Ekstrom et al.,
2011).
PDE7B belongs to a superfamily of enzymes, including 11
members (PDE1−11) which often show specific cellular and
subcellular distribution. The PDEs are all, to different degree,
inhibited by the drugs caffeine and theophylline. When we used
caffeine as an inhibitor in our in vitro studies, no further inhi-
bition was observed, even though we used high concentrations
of caffeine (500µM) which has been shown in previous studies
to inhibit PDEs. These results indicate that no other PDEs are
involved in the hydrolysis of nandrolone decanoate.
Here we show for the first time that androgens induce the
mRNA expression of PDE7B in HepG2 cells. The induction was
observed using androgen concentrations that are in the range
of those observed in healthy volunteers after the administration
of testosterone enanthate (500mg) and nandrolone decanoate
(125mg) (Bagchus et al., 2005; Ekstrom et al., 2011). Our results
indicate that the transcriptional activation of PDE7B may be of
importance after administration of supra-physiological doses of
androgens. The reason why PDE7B was induced already after 2 h,
but not after 5–48 h is not known, but may be due to a negative
feedback on the PDE7B expression. The increase in PDE7B may
be accompanied with a decrease in intra cellular level of cAMP
which may abolish the androgenic effect since cAMP is known
to up-regulate the transcription of PDEs (Manning et al., 1996;
Sasaki et al., 2004). Moreover, testosterone and nandrolone are
both known to be inactivated by UDP-glucuronosyltransferases
2B enzymes (Kuuranne et al., 2003; Jakobsson et al., 2006) which
are highly abundant in HepG2 cells (Nakamura et al., 2008). So
it is possible that the bioactive concentration of the androgens
rapidly decreases after entering the cells and therefore the effect is
diminished.
Testosterone are aromatized to estrogenic metabolites by
CYP19 resulting in estrogenic effects in testosterone abusers e.g.,
gynaecomastia. For nandrolone, the estrogenic effects are miti-
gated as a result of the drug being a progestin, but nevertheless,
effects such as gynaecomastia may still occur at larger doses. In
order to confirm that the up-regulation of PDE7B is due to an
androgenic effect, rather than an estrogenic effect, we used R1881,
a synthetic androgen receptor agonist, free estradiol and estra-
diol cypionate in our cell experiments. Since R1881, but neither
free estradiol nor estradiol cypionate, was shown to increase the
transcription of PDE7B we conclude that the induction in PDE7B
gene expression is indeed an androgenic effect. However, the core
promoter sequence of PDE7B (Accession NM_018945) contains
no androgen response element (ARE). It is possible that an ARE is
situated further upstreams or that the activated AR may bind and
activate other cis-acting elements in the PDE7B gene. Moreover,
the activated AR may interact with other transcription factors
without direct binding to DNA.
PDE7B has been discussed to play a role in various diseases
including asthma, chronic lymphocytic leukemia, Alzheimer,
schizophrenia (Perez-Torres et al., 2003; Zhang et al., 2008;
Ingason et al., 2010; Peiró et al., 2011). PDE7B has also been
discussed as an interesting pharmacological target. For exam-
ple, PDE7B has been proposed as a candidate gene for treatment
response to risperidone (Ikeda et al., 2010). Our result indicates
that PDE7B may have additional pharmacological roles, i.e., in
the metabolism and activation of esterified pro-drugs.
In conclusion here we provide data indicating that PDE7B
plays a role in the activation of esterified androgen drugs.
Moreover, the expression of PDE7B is induced by supra-
physiological concentrations of androgen drugs.
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